Chaeleena Ladd
Family · Gulfport, MSNPI 1518400035
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 677 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 677 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Regeneron Healthcare Solutions, Inc.$976
- Actelion Pharmaceuticals US, Inc.$895
- United Therapeutics Corporation$774
- plus $5K from 28 others
What the payments were for
- Food & beverage$13,45798%
- Education$3082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 137 | $3,120 |
| GSK | 150 | $2,060 |
| Boehringer Ingelheim | 61 | $1,057 |
| Regeneron Healthcare Solutions, Inc. | 36 | $976 |
| Actelion Pharmaceuticals US, Inc. | 31 | $895 |
| United Therapeutics Corporation | 34 | $774 |
| Grifols USA, LLC | 35 | $736 |
| Mylan Specialty L.p. | 23 | $517 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $489 |
| Mallinckrodt Hospital Products Inc. | 16 | $421 |
| Sanofi | 19 | $417 |
| Baxter Healthcare | 16 | $387 |
| Merck | 16 | $375 |
| Electromed, Inc. | 21 | $237 |
| Verona Pharma, Inc. | 8 | $149 |
| ANI Pharmaceuticals, Inc. | 5 | $145 |
| Insmed, Inc. | 6 | $137 |
| Gilead | 6 | $121 |
| Amgen | 4 | $99 |
| Philips North America LLC | 5 | $96 |
| Genentech USA, Inc. | 4 | $81 |
| Bayer | 5 | $79 |
| Viatris Specialty LLC | 3 | $66 |
| Intuitive Surgical | 1 | $64 |
| Johnson & Johnson | 2 | $52 |
| Paratek Pharmaceuticals, Inc. | 3 | $48 |
| Caris MPI, Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Pinnacle Biologics, Inc | 1 | $20 |
| Pfizer | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Pulmonx Corporation | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,764 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 381 | $347,559 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 156 | $129,813 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 121 | $89,585 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $38,172 |
| Spiriva RespimatTiotropium Bromide | 42 | $30,501 |
| Spiriva HandihalerTiotropium Bromide | 12 | $16,602 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $13,784 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 372 | $11,545 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $9,383 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $5,293 |
| Roflumilast | 55 | $4,509 |
| Fluticasone Propionate | 227 | $2,755 |
| Ventolin HfaAlbuterol Sulfate | 45 | $2,284 |
| Azelastine Hcl | 53 | $1,275 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 19 | $1,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,060 | $399,515469 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $3,120 | $144,489194 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $1,057 | $120,087163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Gulfport
- Stephanie RomeroGulfport$28K
- Ashley HouseGulfport$14K
- Justine HuntGulfport$12K
- Laura StevensGulfport$11K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.